Shots:
- Mallinckrodt & Endo to combine their generic pharmaceuticals & Endo’s sterile injectables businesses, later separating the unit, with combined company headquartered in Dublin, Ireland & Endo operating as Mallinckrodt’s subsidiary
- As per the deal, Endo shareholders will receive $80M in cash & own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%, with a $6.7B implied pro forma enterprise value. Combined entity will be listed on NYSE following closing in H2’25
- Merged product portfolio will comprise branded generics incl. Xiaflex, Acthar Gel, Terlivaz, Supprelin LA & Aveed, plus the combined entity will operate 17 manufacturing sites, 30 distribution centers & ~5,700 employees at closing
Ref: Mallinckrodt | Image: Mallinckrodt & Endo
Related News:- Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
